Guardant Health Inc (GH) stock saw a decline, ending the day at $47.21 which represents a decrease of $-1.39 or -2.86% from the prior close of $48.6. The stock opened at $48.26 and touched a low of ...

Investment analysts at Leerink Partnrs lifted their Q4 2024 earnings per share estimates for Guardant Health in a research report issued on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now ...

In terms of valuation, Guardant Health Inc’s market capitalization stands at $6.00 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market ...

Fintel reports that on January 23, 2025, Barclays initiated coverage of Guardant Health (NasdaqGS:GH) with a Overweight ...

Barclays initiated coverage of Guardant Health (GH) with an Overweight rating and $60 price target The firm started the liquid biopsy space ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on GH stock, giving a Buy rating yesterday.Invest with Confidence: ...

On Tuesday, 10 companies—mostly under the space exploration, energy, and quantum computing sectors—registered the highest ...

Wealthcare Advisory Partners LLC acquired a new position in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities ...

Guardant Health has secured Medicare coverage from Palmetto for its blood test to monitor for disease recurrence in patients with colorectal cancer.

BTIG raised the price target for Guardant Health (NASDAQ:GH) to $55.00, up from the previous target of $50.00, while ...

NEW YORK – Guardant Health announced Tuesday that its Guardant Reveal liquid biopsy test has received coverage from Medicare administrative contractor Palmetto GBA to monitor colorectal cancer ...

Guardant Health stock hit a 13-month high Tuesday after Medicare officials agreed to pay for the company's colon cancer blood ...